[PDF] L-theanine in the adjunctive treatment of generalized anxiety disorder: A double-blind, randomised, placebo-controlled trial. | Semantic Scholar (2024)

It is suggested that supplementation of 200–400mg/day of L-THE may assist in the reduction of stress and anxiety in people exposed to stressful conditions.

The hypnotic efficacy of oral melatonin 3 mg was better than oral L-theanine 200 mg in cancer patients having insomnia, and L-theanine had a better hypnotic efficacy when compared to a placebo.

TMM showed an anxiolytic-like and antidepressant-like activity in vivo, which was related to a neuroprotective effect in an in vitro model of excitotoxicity, suggesting a non-benzodiazepine-like mechanism of action.

The findings indicate L-theanine can increase attentional processing of auditory information in a dose-dependent manner, and the linear dose–response attentional effects observed warrant further studies with higher doses of L- theanine.

A single dose of AlphaWave®l-Theanine significantly increased frontal region alpha power compared to placebo in response to an acute stress challenge and was found to be safe and well tolerated by participants.

The high and regular consumption of carbonated/soft drink with sugar tended to be associated with higher level of anxiety in a multicountry sample of overweight subjects with subsyndromal depressive symptoms.

This scoping review sought to systematically map the existing literature on anxiety disorders and nutrition in order to identify associations between dietary factors and anxiety symptoms or disorder prevalence as well as identify gaps and opportunities for further research.

...

...

L-theanine augmentation of antipsychotic therapy can ameliorate positive, activation, and anxiety symptoms in schizophrenia and schizoaffective disorder patients.

It is suggested that chronic (8-week) l-theanine administration is safe and has multiple beneficial effects on depressive symptoms, anxiety, sleep disturbance and cognitive impairments in patients with MDD.

Since sleep problems are a common co-morbidity associated with ADHD, and because disturbed sleep may be linked etiologically to this disorder, L-theanine may represent a safe and important adjunctive therapy in childhood ADHD.

It is suggested that while L‐ theanine may have some relaxing effects under resting conditions, neither L‐theanine not alprazolam demonstrate any acute anxiolytic effects under conditions of increased anxiety in the AA model.

Current evidence supports adjunctive use of SAMe, methylfolate, omega-3, and vitamin D with antidepressants to reduce depressive symptoms.

Current pharmacological treatment options for GAD are described, with focus on benzodiazepines, azapirones, antidepressants and anticonvulsant and antipsychotic drugs.

The MRS findings suggest that l-theanine stabilises the glutamatergic concentration in the brain, which is a possible mechanism underlying the therapeutic effect of l- theanine in schizophrenia.

Based on the evidence available to us, it is recommended that along with the ADs, benzodiazepines be considered a possible first-line therapy in eligible patients based on the discretion and clinical judgment of the treating physician.

It is demonstrated that CBT is a moderately efficacious treatment for anxiety disorders when compared to placebo, and more effective treatments are especially needed for PTSD, SAD, and PD.

...

...